Boswellic acid inhibits expression of acid sphingomyelinase in intestinal cells by Zhang, Yao & Duan, Rui-Dong
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
Boswellic acid inhibits expression of acid sphingomyelinase in 
intestinal cells
Yao Zhang and Rui-Dong Duan*
Address: Gastroenterology and Nutrition Lab, Biomedical Center, B11, University of Lund, Lund, Sweden
Email: Yao Zhang - yao.zhang@med.lu.se; Rui-Dong Duan* - Rui-dong.duan@med.lu.se
* Corresponding author    
Abstract
Background: Boswellic acid is a type of triterpenoids with antiinflammatory and antiproliferative
properties. Sphingomyelin metabolism generates multiple lipid signals affecting cell proliferation,
inflammation, and apoptosis. Upregulation of acid sphingomyelinase (SMase) has been found in
several inflammation-related diseases such as inflammatory bowel diseases, atherosclerosis, and
diabetes.
Methods:  The present study is to examine the effect of 3-acetyl-11-keto-β-boswellic acids
(AKBA), a potent boswellic acid, on acid SMase activity and expression in intestinal cells. Both
transformed Caco-2 cells and non-transformed Int407 cells were incubated with AKBA. After
incubation, the change of acid SMase activity was assayed biochemically, the enzyme protein was
examined by Western blot, and acid SMase mRNA was quantified by qPCR.
Results: We found that AKBA decreased acid SMase activity in both intestinal cell lines in dose
and time dependent manners without affecting the secretion of the enzyme to the cell culture
medium. The effect of AKBA was more effective in the fetal bovine serum-free culture medium.
Among different types of boswellic acid, AKBA was the most potent one. The inhibitory effect on
acid SMase activity occurred only in the intact cells but not in cell-free extract in the test tubes. At
low concentration, AKBA only decreased the acid SMase activity but not the quantity of the
enzyme protein. However, at high concentration, AKBA decreased both the mass of acid SMase
protein and the mRNA levels of acid SMase in the cells, as demonstrated by Western blot and
qPCR, respectively. Under the concentrations decreasing acid SMase activity, AKBA significantly
inhibited cell proliferation.
Conclusion: We identified a novel inhibitory effect of boswellic acids on acid SMase expression,
which may have implications in human diseases and health.
Background
Triterpenoids are compounds belonging to a subgroup of
terpenoids and are sterols in nature. They are metabolites
in plants, playing roles in respiration, photosynthesis,
growth regulation, and chemical defence of the plants [1].
Owning to the findings that triterpenoids have anti-
inflammatory and anti-carcinogenic effects on human,
the interest in the potential application of triterpenoids in
human health and disease is increasing [2,3]. Boswellic
acids are triterpenoids that are present in Boswellia ser-
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rata, a deciduous tree growing in India and China. The
genus Boswellia was also found in other parts of the world
[4]. Boswellic acids have been used as herb medicine for
thousands of years for treatment of inflammatory dis-
eases, mainly rheumatic arthritis [4]. In the last decade,
boswellic acids were shown to also have effects against
brain tumours, hepatitis, and inflammatory bowel dis-
eases (IBD) [2,5]. Multiple biological effects of boswellic
acids have been identified, such as to inhibit 5-lipoxygen-
ase, leukocyte elastase, nuclear factor kappa-B (NF-κB)
and cyclooxygenase [6-8]. We previously showed that
boswellic acids stimulated apoptosis by a mechanism
depending on caspase 8 but independent on Fas/Fas lig-
and pathways [9]. Based on the chemical structure, at least
3 types of boswellic acids, i.e. β-boswellic acid (BA), keto-
β-boswellic acid (KBA), and 3-acetyl-11-keto-β-boswellic
acid (AKBA) have been intensively studied. In many cases,
AKBA is the most effective one [9].
Sphingomyelin (SM) is a type of sphingolipids which is
present in cell membranes and also dietary products. The
hydrolysis of SM is triggered by sphingomyelinase
(SMase), which cleaves phosphocholine headgroup and
turns SM to ceramide. Ceramide is an important molecule
with multiple functions including promoting apoptosis,
inhibiting cell proliferation, enhancing inflammatory
response, and inducing insulin resistance, depending on
the concentrations, cellular locations, and type of tissues
[10]. Ceramide can be further degraded by ceramidase to
sphingosine, which in turn is phosphorylated to sphingo-
sine-1-phosphate (S1P). S1P is a potent molecule that
stimulates cell proliferation, migration, and inflamma-
tion [11]. The divergent effects of sphingolipids and their
metabolites have been summarized in several review arti-
cles [10,12,13].
Based on the optimal pH, at least three types of SMase, i.e.
neutral, alkaline, and acid SMases have been cloned. Neu-
tral SMase is mainly localized on the plasma membrane
and is activated by several cytokines such as TNF-α, and
IL-6 [14]. Alkaline SMase is specifically expressed in the
intestinal tract playing important roles in digestion of die-
tary SM and potentially in preventing colonic tumorigen-
esis [15]. Abnormal forms of alkaline SMase have been
identified in human colon and liver cancers [15,16]. Acid
SMase is a ubiquitous enzyme wildly expressed in various
cell types as a lysosomal enzyme, which hydrolyses SM
that is internalized by endocytosis. Recent studies identi-
fied that the acid SMase gene (SMPD1) can give rise to two
forms of enzyme, one is in the lysosomal and the other is
secreted [17]. Upon stimulation, acid SMase can be trans-
located to the plasma membrane and hydrolyses mem-
brane SM to generate ceramide. Accumulating evidence
indicates that acid SMase may have important implica-
tions in human health because upregulation of acid
SMase has been identified in several diseases such as IBD,
atherosclerosis, and diabetes, as reviewed recently [18].
The present study is to investigate the effects of boswellic
acids, mainly AKBA, on acid SMase expression in the
intestinal cells.
Methods
Materials
Caco-2 cells and Int407 cells were obtained from Ameri-
can Tissue Culture Collection (Rockville, MD). BA, ABA
(3-acetyl-β-boswellic acid), KBA, and AKBA (purity 98%
by HPLC) were obtained from Sabinsa Corporation (Pis-
cataway, NJ, USA). The reagent 4- [3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazoliol]-1, 3-benzene disulfonate
(WST-1) for cell proliferation assay was obtained from
Roche Diagnostics GmbH (Mannheim, Germany). SM
was purified from bovine milk and the choline headgroup
was labelled with [14C-CH3] ([14C]-SM). Antibody against
acid SMase was purchased from Santa Cruz (Falkenberg,
Sweden). The primers for qRT-PCR were purchased from
DNA Technology A/S (Risskov, Denmark). All cell culture
media and other chemical agents used were purchased
from Sigma-Aldrich (Stockholm, Sweden).
Cell culture
Caco-2 cells were cultured in DMEM with 2 mM
glutamine and 4500 mg/l glucose. Int407 cells were cul-
tured in BME with 2 mM L-glutamine. Both media con-
tained 100 IU/ml penicillin, 10 μg/ml streptomycin, and
10% heat inactivated foetal bovine serum (FBS). The cells
were incubated at 37°C in an incubator containing 95%
air and 5% CO2. AKBA and other boswellic acids were dis-
solved in ethanol as a stock and stored at -20°C. When it
was added in the medium, the final concentration of eth-
anol in the medium was 0.1%, and the medium contain-
ing 0.1% ethanol was used as a control. Caco-2 and
Int407 cells were cultured to 80% confluence and incu-
bated with AKBA at different concentrations for 24 h. One
aliquot of the medium was saved for assaying SMase
secreted. The cells were scraped, lysed, sonicated, and cen-
trifuged as described previously [9]. The supernatant was
used for SMase assay and total protein determination. For
time course study, the cells were incubated with AKBA (50
μM) for 6, 12, 24, and 48 h. At each time point, the cells
in both control and experimental groups were lysed and
acid SMase activity and cellular proteins were determined.
To study the effects of AKBA on the cells in the FBS-free
medium, after removing the conventional cell culture
medium, the cells were washed with PBS twice, and incu-
bated in FBS-free medium with AKBA.
Acid sphingomyelinase activity
Acid SMase activity was assayed in 50 mM Tris-maleate
buffer pH 5.0 containing 0.15 M NaCl and 0.12% Triton
X100 [19]. For each determination, 5 μl sample wasLipids in Health and Disease 2009, 8:51 http://www.lipidworld.com/content/8/1/51
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added to 95 μl buffer containing 80 pmole [14C] SM
(~8000 dpm) and incubated at 37°C for 30 min. The reac-
tion was stopped by addition of 0.4 ml chloroform/meth-
anol (2:1, v/v) followed by centrifugation at 10000 g for 5
sec. A portion of the upper phase was taken and the pro-
duction of [14C] phosphocholine was determined by liq-
uid scintillation. The activities of neutral and alkaline
SMase were assayed in the similar way with different opti-
mal pH [19]. The protein concentration was determined
with Bio-Rad DC Protein Assay Kit using albumin as a
standard. The SMase activities were adjusted with the pro-
tein concentrations in the samples and expressed as per-
centage of the values in control group.
To investigate whether AKBA has a direct effect on SMase
activity, 30 μl of cell free extract from Caco-2 cells was
incubated with AKBA at 0, 25, 50, and 100 μM at 37°C for
1 h. The enzyme activities were determined. The changes
of enzyme activity were expressed as percentage of the
control (0 concentration of AKBA).
Western blot analysis
Fifty micrograms of proteins in cell lysate were subjected
to 7.5% SDS PAGE and then transferred to nitrocellulose
membrane electrophoretically overnight. After blocking
the membrane with 5% non-fat dry milk for 2 h, the
membrane was probed with anti-acid SMase antibody
(1:200) for 1.5 h, and then with donkey anti-goat anti-
body (1:50000) conjugated with horseradish peroxidase
for 1.5 h. The specific acid SMase bands were identified by
ECL advance reagents and the remitted light was recorded
on Kodak X-ray film. The whole procedure followed the
instructions of the manufacturer. The membranes were
then stripped and re-probed with anti-β-actin antibody as
a loading control.
RNA isolation and real time reverse transcription PCR
The mRNA levels of acid SMase were quantified by real
time reverse transcription PCR (qRT-PCR). Total RNA in
the cells treated with AKBA was extracted using TRIzol rea-
gents (Invitrogen, Carlsbad, CA) and the cDNA was gen-
erated using 1 μg of total RNA, oligo (dT)18 primer, and a
cDNA Synthesis Kit (Fermentas, Glen Burnie, MD)
according to the instruction of the manufacturer. QRT-
PCR was performed on Bio-Rad iCycler system. The reac-
tion volume was 20 μl, including 10 μl of iQ™ SYBR Green
Supermix (Bio-Rad), 5 μl of diluted cDNA template
(1:500), and 0.3 μl of 20 μM primers. The PCR was initi-
ated at 95°C for 3 min to activate the polymerase, fol-
lowed by 40 cycles of 95°C for 15 sec, and 60°C for 15
sec. Finally the melting curve analysis was performed to
confirm that a single product was amplified and no dim-
mer was interfered with the reaction. Reactions were per-
formed in triplicate. The cycle threshold (Ct) was
analyzed automatically by the iQ™5 Optical System Soft-
ware (Bio-Rad). Relative expression of acid SMase mRNA
was normalized to the level of an internal control gene
(GAPDH) by using the 2ΔΔCT method. The primers used in
this study were as follows: GAPDH (forward,
5'CATGAGAAGTATGACAACAGCCT3'; reverse, 5'
AGTCCTTCCACGATACCAAAGT3') and acid SMase (for-
ward, 5'TGGCTCTATGAAGCGATGGC3'; reverse,
5'TTGAGAGAGATGAGGCGGAGAC3').
Cell proliferation assay
Cell proliferation was assayed by determination of the
cleavage of tetrazolium salt (WST-1) to formazan by mito-
chondrial dehydrogenase. The amount of formazan
formed is proportional to the viable cell numbers. The
cells (2×104) were cultured in a 96-well plate and stimu-
lated with AKBA of different concentrations for 24 h.
WST-1 was then added in each well. After incubation for
1 h, the production of formazan was read in a microplate
reader (Bio-Rad) at 405 nm against 620 nm as a back-
ground. The results were expressed as percentage of the
control.
Statistical analysis
Each experiment was conducted at least in triplicate in at
least three separate experiments. Statistical analysis was
performed by using Student's t-test and one-way ANOVA.
Data are presented as mean ± standard error and p < 0.05
was considered statistically significant.
Results
AKBA decreased acid SMase activity in Caco-2 cells
After culturing Caco-2 cells with AKBA, the acid SMase
activities in the cells were decreased in a dose-dependent
manner (Figure 1A). The effects occurred at concentra-
tions of AKBA higher than 25 μM. About 31% inhibition
was induced by 50 μM AKBA and 62% inhibition was
induced by 100 μM AKBA. No similar changes were iden-
tified for either neutral or alkaline SMase activity after
AKBA stimulation (data not shown).
The time course of AKBA (50 μM)-induced inhibition of
acid SMase was shown in panel B of Figure 1. The acid
SMase activity was decreased by 16%, 37%, and 59%,
when the cells were treated with AKBA for 12, 24, and 48
h, respectively.
We also performed an experiment in which Caco-2 cells
were incubated with AKBA in the medium without FBS.
We found that under this condition, 20% decrease of acid
SMase activity could be induced by AKBA at even 6.25 μM
(P = 0.058) and 50% decrease by AKBA at 12.5 μM (P =
0.002) (Figure 2). Because culturing the cells in medium
without FBS allows the measurement of the released acid
SMase [17], we measured the acid SMase activity in this
medium after AKBA treatment. No significant change ofLipids in Health and Disease 2009, 8:51 http://www.lipidworld.com/content/8/1/51
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acid SMase activity induced by AKBA was identified. Nei-
ther acid SMase activity was increased in the normal
medium with FBS (data not shown).
To compare the efficacy of different boswellic acids, we
treated Caco-2 cells with different boswellic acids includ-
ing BA, ABA, KBA, and AKBA at the concentration of 50
μM for 24 h. All the boswellic acids tested reduced the acid
SMase activity and AKBA was the most effective one (Fig-
ure 3).
AKBA also decreased acid sphingomyelinase activity in 
Int407 cells
To examine whether AKBA also influences acid SMase
activity in nontransformed cells, we treated Int407 cells
with AKBA at different concentrations or for different
Changes of acid SMase activity in Caco-2 cells treated with  AKBA Figure 1
Changes of acid SMase activity in Caco-2 cells 
treated with AKBA. (A): The cells were treated with 
AKBA in different concentrations for 24 h and acid SMase 
activities in cell lysate were determined. (B): The cells were 
treated with AKBA (50 μM) or without AKBA as control for 
different times. After treatment, the enzyme activity was 
determined in comparison with the control group at each 
time point. The activities were adjusted to protein levels in 
the cells and expressed as percentage of the control. Results 
are mean ± standard error from 3 separated experiments. * 
P < 0.05, **P < 0.01, and *** P < 0.001 compared with the 
control.
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Effects of AKBA on Caco-2 cells cultured in FBS-free medium Figure 2
Effects of AKBA on Caco-2 cells cultured in FBS-free 
medium. The cells were cultured conventionally to 80% 
confluence and then treated with AKBA in DMEM without 
FBS. Acid SMase activities in cell lysate were determined. The 
activities in control group were taken as 100%. **P < 0.01 
compared with the control.
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Comparison of the efficacy of different boswellic acids Figure 3
Comparison of the efficacy of different boswellic 
acids. Caco-2 cells were treated with 50 μM BA, ABA, KBA, 
or AKBA for 24 h. Acid SMase activities in cell lysate were 
determined. The activities in control group were taken as 
100%. Results are mean ± standard error from 3 separated 
experiments. The statistic significance was analyzed by one-
way ANOVA followed by Tukey test. The statistic significan-
ces were indicated in the figure. * P < 0.05, ** P < 0.01, and 
*** P < 0.001.
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times. The results were similar in general to those
obtained from the studies with Caco-2 cells (Figure 4),
although the Int407 cells appeared to be more sensitive to
AKBA than Caco-2 cells, if we compare both the dose and
time dependent curves in this figure with Figure 1.
Mechanism underlying the reduced acid SMase activity by 
AKBA
To identify the mechanism behind the reduced acid
SMase activity by AKBA, we first examined whether AKBA
could directly affect the acid SMase activity. We incubated
the non-stimulated cell lysate in test tubes with AKBA up
to 100 μM at 37°C for 1 h followed by acid SMase assay.
Such a treatment did not reduce the acid SMase activity in
the lysate (data not shown), suggesting that the reduction
of acid SMase activity by AKBA occurs only in the intact
cells and may not be a direct inhibition of AKBA on the
enzyme protein.
To examine whether the reduced acid SMase activity was
associated with changes of the enzyme protein, Western
blot was performed. After treating Caco-2 cells with AKBA
in different concentrations, we found no significant
reduction of the acid SMase mass by AKBA up to 50 μM.
However, 100 μM AKBA significantly decreased acid
SMase levels as shown in Figure 5. Such a reduction was
not caused by a loading error, as similar levels of β-actin
were present in all samples.
To further understand the mechanism underlying the
changed acid SMase protein, real time RT-PCR was per-
formed. We found that the mRNA of acid SMase was not
significantly changed in cells treated with AKBA up to 50
μM, but a significant reduction (P < 0.01) of acid SMase
mRNA was found in cells treated with 100 μM AKBA (Fig-
ure 6).
AKBA inhibited cell proliferation in Caco-2 cells
When the cells were treated with AKBA at the same con-
centrations used in the experiment, the cell proliferation
was inhibited in a dose-dependent manner. AKBA at 50
μM inhibited the cell proliferation by 52%, whereas 100
μM AKBA strongly inhibited the cell proliferation by 90%
(Figure 7).
Changes of acid SMase activity in Int407 cells treated with  AKBA Figure 4
Changes of acid SMase activity in Int407 cells treated 
with AKBA. (A): Non-transformed Int407 cells were 
treated with AKBA in different concentrations for 24 h and 
acid SMase activities in the cell lysate were determined. (B): 
The cells were treated with AKBA (50 μm) or without 
AKBA as control for different times. After treatment, the 
enzyme activity was determined in comparison with the con-
trol group at each time point. The activities in control group 
were taken as 100%. Results are mean ± standard error from 
3 separated experiments. *** P < 0.001 compared with the 
control.
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Western blot showing the effect of AKBA on acid SMase  expression Figure 5
Western blot showing the effect of AKBA on acid 
SMase expression. Caco-2 cells were treated with AKBA 
in different concentrations for 24 h. Fifty micrograms of pro-
teins were subjected to 7.5% SDS-PAGE and transferred to 
nitrocellulose membrane electrophoretically. The membrane 
was probed with anti-acid SMase antibody first and then a 
secondary antibody. The bands were identified by ECL 
advance reagents (upper panel). In the lower panel, the mem-
brane was stripped and re-probed with anti-β-actin antibody. 
The results from two separate samples for each concentra-
tion group are presented. Similar results were obtained from 
other two experiments.
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Discussion
In the present study we identified a novel inhibitory effect
of boswellic acids on acid SMase activity in cell culture.
The effect was dose-dependent. About 30% inhibition
could be induced by 50 μM AKBA in the presence of FBS
and by 6~12 μM AKBA in the absence of FBS. The
increased efficacy of AKBA in the absence of FBS indicates
a protective effect of serum against AKBA. The reduction
of acid SMase activity occurred 12 h after incubation and
was generally similar in transformed intestinal Caco-2
cells and non transformed Int407 cells.
The reduced acid SMase activity was not caused by a direct
inhibition of AKBA on acid SMase protein, because in
vitro incubation of AKBA with cell free extract did not
reduce the enzyme activity. Since acid SMase gene can give
rise to two forms of the enzyme, one in the lysosomes and
the other secreted [17], we also examined whether the
reduced enzyme activity in the cell extract was due to an
increased secretion of the enzyme. By simultaneous meas-
uring of the activity in the cell free extract and medium
with or without serum, we did not find obvious secretion
of acid SMase to the medium before and after AKBA stim-
ulation. Since previous finding of a secreted acid SMase
was mainly in studies with endothelial cells [18], the fail-
ure to identify secretion of acid SMase in the intestinal
cells may indicate a cell type specificity. Although acid
SMase was found in the intestinal lumen previously, the
activity is likely derived from the shedding of the intesti-
nal mucosal cells [20].
To identify the mechanism underlying the decreased acid
SMase activity in the cells, both Western blot and qPCR
were performed. We found that at 50 μM, AKBA did not
affect the contents of acid SMase protein and acid SMase
mRNA, although the enzyme activity was decreased about
30%. The results indicate that at this concentration, the
reduced activity was not caused by an inhibition of gene
transcription and translation, but presumably by an inter-
ference of post-translational modification or maturation
of the enzyme. It has been demonstrated that post-trans-
lational modifications of acid SMase involve glycosyla-
tion, phosphorylation, and proteolytic processing, which
are important for maturation of the enzyme [18]. AKBA
has been shown to affect various protein kinases such as
CDK4 [21], PI3K [22,23], IKK [8], and MAPK [22], and
also some types of phosphatase [24] in various cell types
including the intestinal cells. Whether these effects could
affect acid SMase activity is of interest for further investi-
gation. However, at high concentration, AKBA inhibited
the expression of acid SMase at the transcriptional levels,
as convincingly demonstrated by the results of Western
blot and qPCR.
The finding that AKBA inhibits both activity and expres-
sion of acid SMase in the intestinal cells may have impli-
cations in the intestinal diseases, particularly IBD.
Previous studies in animal models showed that AKBA
inhibited the IBD induced by indomethacin and
decreased the mucosal damage, with a mechanism linked
Changes of acid SMase mRNA in Caco-2 cells after AKBA  stimulation Figure 6
Changes of acid SMase mRNA in Caco-2 cells after 
AKBA stimulation. Total RNA was extracted from Caco-
2 cells treated with AKBA and subjected to qRT-PCR to 
measure the expression of acid SMase mRNA. GAPDH was 
used as a reference gene. Ct value and relative levels of 
mRNA were calculated by the iQ™5 Optical System Soft-
ware. Similar results were obtained from other two experi-
ments. **P < 0.01.
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Effects of AKBA on cell proliferation Figure 7
Effects of AKBA on cell proliferation. Caco-2 cells were 
treated with AKBA in different concentrations for 24 h. Cell 
proliferation was assayed by the cleavage of WST-1 reagent. 
The results are expressed as mean ± standard error from 3 
separate experiments. *** P < 0.001 compared with control.
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to a decrease in leukocyte-endothelial cell interaction
[25]. Our study indicates an additional mechanism for
AKBA to inhibit the intestinal inflammation. Recently
Sakata et al reported that acid SMase might play important
roles in promoting the development of IBD, because inhi-
bition of acid SMase resulted in significantly improve-
ments of the inflammation in both animal and cell
culture studies [26]. In agreement with the concept, treat-
ing intestinal cells with exogenous SMase from bacteria
was recently shown to induce the damage of the intestinal
barrier functions [27]. In supporting the hypothesis, our
study also showed that AKBA inhibited cell proliferation
at the concentrations inhibiting acid SMase activity.
In addition, the inhibition of acid SMase activity by AKBA
may have implications in other diseases. Ceramide gener-
ated from hydrolysis of SM was previously considered in
general an important molecule that inhibits cell prolifera-
tion and induces apoptosis. This concept has been
changed as many studies showed that the effects of cera-
mide are more complicated varying with both locations
and ways to be generated [12]. Ceramide generated by
acid SMase in several cases has been shown to be proin-
flammatory and may stimulate cell proliferation. Several
inflammatory factors such as TNF-α and LPS are able to
stimulate acid SMase expression [28]. Increased acid
SMase expression has been found in various diseases that
threaten human health, such as atherosclerosis, heart fail-
ure, insulin resistance, cystic fibrosis, lung inflammation,
and peritonitis as recently reviewed [18]. In many cases,
inhibition of acid SMase improved the pathogenesis of
the diseases. Studies with acid SMase -/- mice also support
pathogenic effects of acid SMase in some diseases men-
tioned above [29-31].
Based on the literatures above, AKBA might potentially be
a candidate of a new type of antiinflammatory drugs tar-
geting acid SMase. It is stable and safe. However, the
absorption of boswellic acids after oral administration is
relatively poor and the absorbed boswellic acids are accu-
mulated in the intestinal mucosal cells [32]. This could
favour its potential utilization against intestinal diseases
such as IBD, as it may increase the exposure of colon to
AKBA. On the other hand, pharmacokinetic studies
showed that AKBA in plasma did not undergo phase 1
metabolism [33], whether it can be given intravenously in
a relatively low dose is an interesting question for investi-
gation.
Conclusion
We identified a novel inhibitory effect of AKBA on acid
SMase expression in intestinal cells, which may have
implications in human diseases and health.
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